Nutriband Inc. Common Stock (NTRB)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings and a margin of safety, and Nutriband does not yet fit that mold. It is developing transdermal pharmaceutical products, led by AVERSA Fentanyl, an abuse-deterrent fentanyl patch. The idea has regulatory and clinical barriers, and an agreement with Kindeva supports development, but no real moat is proven until it sells profitably. The filed numbers show a very small business: in fiscal Q2 2027, the quarter ended 2026-07-31, revenue was $437,514 and net income was -$880,561. For FY2026, the year ended 2026-01-31, revenue was $2.0M and net income was -$8.2M, or EPS -$2.58. FY2025 had $2.1M of revenue and a -$10.5M net loss, and FY2024 had $2.1M of revenue and a -$5.5M net loss. So losses are persistent, even if the FY2026 loss narrowed from FY2025. Trailing free cash flow is -$3.6M, a -4.6% FCF yield by FairStock's calculation. At the 2026-10-13 close, the market cap was $79.3M, P/B was 14.82, and ROE was -100.75%; the negative P/E means earnings offer no valuation anchor. The low D/E of 0.04 and Altman Z-Score of 38.61 suggest debt is not the immediate problem, but the Piotroski F-Score of 4/9 and FairStock Score of 21/100 reflect fragility. The Lynch category is none, because it has lost money in each of the last four years. This is a pipeline speculation, not a Graham-style bargain.

In plain English: Nutriband is a small healthcare company developing skin patches, including an abuse-deterrent fentanyl patch. It is not profitable yet: revenue is tiny, it loses money, and cash flow is negative. At $6.52 a share, the price looks expensive compared with its sales and accounting value, although the stock could be worth much more if its main product succeeds.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2027 10-Q (period ended 2026-07-31) · fiscal Q1 2027 10-Q (period ended 2026-04-30) · fiscal Q3 2026 10-Q (period ended 2025-10-31) · fiscal Q2 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-01-31) · FY2025 10-K (period ended 2025-01-31) · FY2024 10-K (period ended 2024-01-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer